BerberineBerberine HCl · 4 claims

Across 50 studies and 4,150 participants, berberine added to hypoglycaemic drugs reduced fasting plasma glucose by 0.99 mmol/L, 2-hour postprandial glucose by 1.07 mmol/L and HbA1c by 0.69% (all p<0.01). Used alone the effects were smaller: FPG −0.59 mmol/L (p=0.048), 2hPBG −1.57 mmol/L.

Effect size depends on where you start — a separate meta-analysis found the glucose-lowering effect related to baseline FPG and HbA1c. It did not increase total adverse events (RR 0.73, 95% CI 0.55–0.97) or hypoglycaemia risk (RR 0.48, 95% CI 0.21–1.08).

The quality caveat is consistent across reviews. An earlier meta-analysis of 14 trials and 1,068 participants stated that methodological quality was generally low and that findings should be interpreted carefully given small sample sizes and unidentified risks of bias. A later analysis found publication bias on HbA1c and total cholesterol by Egger test, though trim-and-fill did not change the conclusion.

• MetaWang J, Bi C, Xi H, Wei F. Effects of administering berberine alone or in combination on type 2 diabetes mellitus Front Pharmacol 2024 · PMID 39640489 · 50 studies, 4,150 participants
• MetaGlucose-lowering effect of berberine on type 2 diabetes: systematic review and meta-analysis PMID 36467075 · PROSPERO CRD42021292975
• MetaBerberine in the treatment of type 2 diabetes mellitus: systematic review and meta-analysis 14 trials, 1,068 participants · “methodological quality was generally low”

Berberine alone reduced LDL-C by 0.30 mmol/L, total cholesterol by 0.30 mmol/L and triglycerides by 0.35 mmol/L. A separate synthesis in dyslipidaemia reported TC −0.47, TG −0.28 and LDL-C −0.38 mmol/L.

One review argued the LDL reduction is clinically meaningful by ATP III standards. Egger testing found publication bias on the total cholesterol outcome, though trim-and-fill left the conclusion intact.

• MetaEfficacy and safety profile of berberine in improving risk factors for cardiovascular disease: meta-analysis of randomized double-blind trials Publication bias detected on HbA1c and TC by Egger test
• MetaMeta-analysis of Chinese clinical trials on berberine and blood lipids Also documents the CYP450 interaction data

Compared directly against oral hypoglycaemics including metformin, glipizide and rosiglitazone, berberine did not demonstrate significantly better glycaemic control, though it did show a mild antidyslipidemic effect the comparators lacked.

The picture that emerges across syntheses is of a reasonable adjunct rather than a replacement: added to existing drugs it improves control, used instead of them it does not clearly match them. The popular framing of berberine as “nature's metformin” is not what the head-to-head data shows.

• MetaBerberine in the treatment of T2DM: comparison against oral hypoglycaemics 14 trials, 1,068 participants

Repeated oral administration of 0.3 g berberine three times per day decreased CYP2D6, CYP2C9 and CYP3A4 activity in healthy subjects. Between them these enzymes metabolise a very large share of common prescription medicines.

The doses used in three of the reviewed lipid trials matched this level and in seven were higher. Reviewers explicitly note that potential herb-drug interactions should be considered.

This is the most under-communicated fact about berberine. It is sold beside vitamins as a metabolic supplement, and it behaves pharmacologically like a drug that interacts with other drugs.

• PKCYP2D6, CYP2C9 and CYP3A4 inhibition following repeated oral berberine 0.3 g three times daily in healthy subjects Reported alongside the lipid meta-analysis